10-Q: SS Innovations International Reports Increased Revenue but Faces Restatement and Control Issues in Q2 2024

SS Innovations International reported a significant increase in revenue for the second quarter of 2024, but also disclosed the need to restate prior financial statements and identified weaknesses in internal controls.

Summary

• SS Innovations International, Inc. reported its financial results for the quarter ended June 30, 2024, showing a substantial increase in revenue compared to the same period last year.
• The company's revenue for the three months ended June 30, 2024, was $4,386,051, compared to $1,575,306 for the same period in 2023.
• For the six months ended June 30, 2024, revenue reached $11,617,011, up from $3,086,685 in the first half of 2023.
• The company sold 9 surgical robotic systems in the second quarter of 2024, bringing the total to 33 systems sold and 5 installed on a pay-per-use basis.
• Despite the revenue growth, the company reported a net loss of $2,931,834 for the three months ended June 30, 2024, and a net loss of $5,579,695 for the six months ended June 30, 2024.
• The company also disclosed that its previously issued financial statements for 2022, 2023 and the first quarter of 2024 need to be restated due to material issues identified during an internal review and a reaudit by BDO India LLP.
• The company's internal controls were deemed not fully effective due to a lack of written documentation and complete segregation of duties.
• The company has raised $4.45 million through short-term convertible promissory notes and $2 million through non-convertible promissory notes to support its operations.
• As of June 30, 2024, the company had a working capital surplus of $4.90 million and an accumulated deficit of $32.01 million.

Sentiment

Score: 4

Explanation: The document presents a mixed picture. While there is strong revenue growth and expansion, the need for restatement, internal control weaknesses, and ongoing losses raise significant concerns. The company's reliance on short-term debt and the uncertainty of future funding also contribute to a negative sentiment.

Positives

• The company experienced substantial revenue growth in the second quarter of 2024.
• The company has successfully increased its installed base of surgical robotic systems.
• The company has secured additional funding through promissory notes.
• The company has a growing number of surgical procedures performed on its systems.
• The company is actively pursuing regulatory approvals in key markets.

Negatives

• The company reported a net loss for both the three and six months ended June 30, 2024.
• The company's previously issued financial statements need to be restated.
• The company identified weaknesses in its internal controls.
• The company has a significant accumulated deficit of $32.01 million.
• The company's auditor was barred from appearing before the SEC, requiring a reaudit of past financial statements.

Risks

• The company's ability to continue as a going concern is dependent on raising additional capital.
• The restatement of financial statements could negatively impact investor confidence.
• Weaknesses in internal controls could lead to further financial reporting issues.
• The company faces competition in the surgical robotics market.
• The company's expansion plans could be hindered by a lack of funding.

Future Outlook

The company anticipates regulatory approvals in the United States and the EU in the second half of 2025 and is making efforts to raise long-term funds to support its expansion plans.

Management Comments

• The company is relentlessly pursuing its vision of increasing the penetration of robotics surgeries in regions and countries which were hitherto completely forgotten.
• The company is constantly working on making its surgical robotics technology even more user-friendly, easy to operate and even more cost effective so as to make its benefits reach to larger communities across the globe.

Industry Context

The company is aiming to democratize access to advanced surgical robotics technologies at relatively affordable costs, addressing the limited access to such systems in developing countries. This aligns with a broader trend of increasing adoption of robotic surgery globally, but with a focus on underserved markets.

Comparison to Industry Standards

• The company's focus on affordability and accessibility differentiates it from established players like Intuitive Surgical, which primarily targets developed markets with higher-priced systems.
• The company's sales of 33 systems and 5 pay-per-use installations is relatively small compared to the global installed base of major robotic surgery companies.
• The company's revenue growth is significant, but its net losses and need for restatement highlight the challenges of scaling a medical device business.
• The company's reliance on short-term debt financing is not uncommon for early-stage medical device companies, but it also indicates a need for more stable long-term capital.

Management Changes

Legal Proceedings

• There are no legal proceedings currently pending or threatened against the company other than those previously reported.

Related Party Transactions

• The company has $1,297,410 in amounts due from related parties as of June 30, 2024.
• The company sold $2,450,000 in convertible promissory notes to five investors, including Sushruta Pvt Ltd.
• The company issued $2,000,000 in promissory notes to Sushruta Pvt Ltd.
• In July 2024, the company raised an additional $500,000 from Sushruta Pvt Ltd.

Stakeholder Impact

• Shareholders face potential dilution from future capital raises.
• Employees may be impacted by the company's financial challenges and potential restructuring.
• Customers may be concerned about the company's ability to provide ongoing support and maintenance.
• Suppliers may face increased risk due to the company's financial instability.
• Creditors may be concerned about the company's ability to repay its debts.

Next Steps

• The company will amend this report as soon as practicable after the required auditor review is completed.
• The company will include any necessary adjustments or restatements for the periods presented.
• The company will continue to work on implementing a new ERP system.
• The company will continue to pursue regulatory approvals in the United States and the EU.
• The company will continue to seek additional funding to support its operations and expansion.

Key Dates

Keywords

surgical robotics, medical devices, financial results, revenue growth, internal controls, restatement, promissory notes, SSI Mantra, healthcare technology, robotic surgery